Ollin Biosciences · Series A

Biotech advancing best-in-class bispecific antibody therapies for eye disease, using AI and

Amount

$100M

Round

Series A

Valuation

—

Announced

—

Investors

Participating investors

ARCH Venture Partners Mubadala Capital Polaris Partners Monograph Capital